Search

Displaying results 1991 - 2000 of 10000 in total
  1. Drug

    Normethadone

    go.drugbank.com/drugs/DB11609
    ApprovedIllicit

    Normethadone is used as an opioid antitussive in combination with [DB11610]. It is marketed in Canada by Valeant under the tradename Cophylac.

  2. Drug

    Artemether

    go.drugbank.com/drugs/DB06697
    ApprovedInvestigational

    Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. … </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.

  3. Drug

    Alglucosidase alfa

    go.drugbank.com/drugs/DB01272
    ApprovedInvestigational

    Aglucosidase alfa is produced by recombinant DNA technology in a Chinese hamster ovary cell line. … It is used for the treatment of Pompe disease (GAA deficiency) in infants and pediatric patients.

  4. Drug

    Chenodeoxycholic acid

    go.drugbank.com/drugs/DB06777
    ApprovedInvestigational

    Chenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. … It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decrease the formation of gallstones.

  5. Drug

    Meningococcal polysaccharide vaccine group C

    go.drugbank.com/drugs/DB13890
    ApprovedInvestigational

    *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. … It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.

    Mixtures: Menjugate 10 Mikrogramm Injektionssuspension in einer Fertigspritze, Menomune-A/c/y/w-135
  6. Drug

    Olaparib

    go.drugbank.com/drugs/DB09074
    ApprovedInvestigational

    [L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell … [L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820]

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  7. Drug

    Vanzacaftor

    go.drugbank.com/drugs/DB18373
    ApprovedInvestigational

    [L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor … ], a CFTR potentiator, for the treatment of patients with responsive CFTR mutations.

  8. Drug

    Technetium Tc-99m nofetumomab merpentan

    go.drugbank.com/drugs/DB09336
    ApprovedWithdrawn

    [A32115] The NR-LU-10 antibody is directed against a 40 kDa glycoprotein antigen expressed in a variety of cancers and some normal tissues. … Technetium Tc-99m nofetumomab merpentan (Tc-99m nm) consists of a Fab fragment of an IgG2b of the pancarcinoma murine antibody NR-LU-10.

  9. Drug

    Obiltoxaximab

    go.drugbank.com/drugs/DB05336
    Approved

    Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa. … Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin.

  10. Drug

    Ulobetasol

    go.drugbank.com/drugs/DB00596
    Approved

    Ulobetasol is a highly potent corticosteroid.[A215597] It is structurally related to [clobetasol]. … [L15047,L15052,L15102] Ulobetasol was granted FDA approval on 17 December 1990.[L15047]